Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.
Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.